Important note: Information in this article was accurate in November 2000. The state of the art may have changed since the publication date.
Although the non-nucleoside analogues nevirapine (Viramune) is an effective part of anti-HIV regimens, it is associated with a number of side effects, including the following:
The most common side effect linked to the use of nevirapine is rash. As many as 17% of people exposed to this drug develop a rash, and in about 0.5% the rash is so severe that it becomes life-threatening, a condition called Stevens-Johnson syndrome.
In their everyday experience of caring for people with HIV/AIDS (PHAs), doctors in several major medical centres in the U.S. have found that side effects from nevirapine tend to be "more frequent and severe" in women compared to men. As a result the doctors decided to review the medical records of their patients who received nevirapine to confirm their findings and perhaps understand why women may be at increased risk for nevirapine-related rash.
Researchers reviewed the medical records of 358 subjects (27% female, 73% male) who had been exposed to nevirapine. According to the researchers' analysis, women are about seven times more likely than men to develop "severe rash." The researchers are not certain why this difference occurs. They did find that people who had more than 200 CD4+ cells at the time they began using nevirapine were more likely to develop "severe rash" than people with fewer CD4+ cells. Factors such as viral load, age, race or interactions with other medications were not significantly associated with developing severe rash.
Nevirapine is not the only drug that seems to cause more severe side effects in women. Other researchers have found that women are also more likely than men to develop skin reactions to the following products:
Researchers note that because more women are becoming HIV+, it is important to enroll them in clinical trials to find out if drugs have a different impact on them than they do on men.
1. Bersoff-Matcha SJ, Miller WC, Aberg JA, et al. Sex differences in nevirapine rash. Clinical Infectious Diseases 2001;32:124-129.
20001115
CATE11207
Copyright © 2000 - TreatmentUpdate. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Editor, The Canadian AIDS Treatment Information Exchange, 555 Richmond St. West, Suite 505, Box 1104, Toronto, ON, M5V 3B1 • Phone: 416-203-7122 • Toll Free: 1-800-263-1638 • Fax: 416-203-8284 http://www.catie.ca.
ÆGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
ÆGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1990, 2000. ÆGiS & the Sisters of Saint Elizabeth of Hungary. All materials appearing on ÆGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of ÆGIS, or the party credited as the provider of the content.